Abstract with faint, scattered DNA double helix patterns, evoking cell and gene therapy

2026 Cell and Gene Therapy Report

Turning Breakthrough Science Into Commercial Patient Access

Cell and gene therapies (CGTs) are redefining what’s possible in medicine as they continue to move from scientific progress to real-world impact across oncology, autoimmune disease, ophthalmology, and beyond. As the pipeline expands, innovation is outpacing the operational, financial, and infrastructure changes needed to ensure broad patient access to cell and gene therapies.

The 2026 Cell and Gene Therapy Report examines the opportunities and obstacles shaping patient access today and what healthcare stakeholders must do next to improve it. Now in its third year, the report expands its research beyond oncology to other specialties, examines payer viewpoints in greater depth, amplifies patient voices, and convenes industry leaders to discuss AI’s role in streamlining delivery and access.

InspiroGene's 2026 Cell and Gene Therapy Report: 'Building the Bridge' with crowd forming a DNA helix leading to a bridge.

968

late-stage CGTs in development, including 192 therapies targeting 77 autoimmune diseases

32

CGT patients, on average, are treated annually by oncologists surveyed, up from 17 in 2024

34%

of oncologists identify insurance approval as the largest drop-off point

3 in 5

rheumatologists and ophthalmologists expect to treat CGT patients directly rather than refer them elsewhere

US map with location markers across all 50 states and Puerto Rico, indicating cell and gene therapy center locations.

See the Treatment Center Map

Geography remains one of the biggest barriers to cell and gene therapy today. Most CGT care today remains concentrated in academic medical centers and major cities, and the number of treatment sites has held largely flat over the past year. This year, for the first time, the map also charts where CGT clinical trials are underway, highlighting another path to these therapies for patients.

Explore the interactive map to see where treatment and clinical trials are available today and where gaps persist.

Go to the map

CGT Facility Overview

Explore how InspiroGene makes your CGT product a priority from the moment it’s received to preparation, shipping, and more, with dedicated high-tech capabilities and a focus on quality.

Treatment Center Experience

A successful treatment center experience is enabled by strong launch readiness, efficient site activation, and reliable patient access. InspiroGene is designed to make that experience simple, consistent, and scalable so approved therapies translate seamlessly into patient care.

InspiroLink is designed for cell, gene, and advanced therapy treatment providers, making ordering, scheduling, and tracking products effortless.

Connect with us

Icon representing an online contact profile for the Contact Us page.
CONTACT US

Frequently asked questions

Question mark in a speech bubble icon for Frequently Asked Questions.
GO TO FAQs